Scarica l'app Stockscreener
2.09
6.09%
0.12
Dopo l'orario di chiusura:
2.08
-0.010
-0.48%
Black Diamond Therapeutics Inc Borsa (BDTX) Ultime notizie
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX) - Seeking Alpha
BDTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BDTX SEC FilingsBlack Diamond Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali - Moomoo
Black Diamond Therapeutics touts Silevertinib lung cancer data, eyes FDA path - MSN
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Raman Prakash - Moomoo
Black Diamond Therapeutics 2026 Annual Stockholder Meeting Results and Voting Outcomes - Minichart
Form 4 Black Diamond Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
[Form 4] Black Diamond Therapeutics, Inc. Insider Trading Activity - Stock Titan
Black Diamond (BDTX) director awarded 40,000 stock options at $1.71 - Stock Titan
Black Diamond Therapeutics (BDTX) director awarded 40,000 stock options at $1.71 - Stock Titan
Director Garry Menzel granted 40,000 BDTX stock options at $1.71 strike - Stock Titan
Black Diamond (NASDAQ: BDTX) director receives 40,000 stock options at $1.71 - Stock Titan
Black Diamond Therapeutics (BDTX) awards 40,000-share option grant - Stock Titan
Black Diamond Therapeutics (BDTX) 2026 meeting backs directors, auditor and annual say-on-pay - Stock Titan
Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) added to Russell 2000 Index - marketscreener.com
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Value Benchmark - marketscreener.com
Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) added to Russell 3000E Index - marketscreener.com
Enterprise value to EBITDA forward of Black Diamond Therapeutics, Inc. – NASDAQ:BDTX - TradingView
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 3000E Value Benchmark - marketscreener.com
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Black Diamond Therapeutics (BDTX) AGM 2026 Summary - Quartr
Price to sales forward of Black Diamond Therapeutics, Inc. – NASDAQ:BDTX - TradingView
Price to book forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX - TradingView
Black Diamond Therapeutics, Inc. Actuals & Estimates (NASDAQ:BDTX) - TradingView
Enterprise value to EBIT forward of Black Diamond Therapeutics, Inc. – NASDAQ:BDTX - TradingView
Price to earnings forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX - TradingView
Price to sales forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX - TradingView
Enterprise value to revenue forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX - TradingView
BDTX shares gain 11% in a week: Here's what you should know - MSN
BDTX Forecast — Price Target — Prediction for 2027 - TradingView
Black Diamond Therapeutics Inc (BDTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Form 4 Black Diamond Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
Ali Behbahani of Black Diamond (NASDAQ: BDTX) receives 8,961-share award - Stock Titan
Black Diamond Therapeutics Inc (BDTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Black Diamond Therapeutics Inc (BDTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Black Diamond Therapeutics Inc (BDTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Black Diamond Therapeutics Inc - TradingKey
Black Diamond Therapeutics Inc (BDTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Black Diamond Therapeutics Inc (BDTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Black Diamond Therapeutics Inc (BDTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Black Diamond Therapeutics Inc (BDTX) Institutional Confidence - TradingKey
Black Diamond Therapeutics (BDTX) Holds Near Support Amid Modest DeclineEqual Weight ETF - newsline.com
Black Diamond Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss as Pipeline AdvancesEarnings Recovery Stocks - newsline.com
Black Diamond Therapeutics (BDTX) Dips 3.85%: Support Test in Focus After Recent DeclineOverbought Signal Alerts - newsline.com
BDTX News | BLACK DIAMOND THERAPEUTICS I (NASDAQ:BDTX) - ChartMill
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM) and Viridian Therapeutics (VRDN) - The Globe and Mail
Black Diamond Therapeutics(BDTX) Stock Options Chain | Quotes & News - Moomoo
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path - sharewise.com
Black Diamond Therapeutics (BDTX) Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesCapex Guidance - dars.gov.et
Black Diamond Therapeutics lung cancer drug shows 15.2-month PFS in phase 2 study - MSN
Black Diamond Therapeutics (BDTX) Jefferies Global Healthcare Conference 2026 summary - Quartr
Wedbush Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
0.86%
3.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):